The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations ; volume:264 ; number:12 ; day:6 ; month:9 ; year:2017 ; pages:2351-2374 ; date:12.2017
Journal of neurology ; 264, Heft 12 (6.9.2017), 2351-2374, 12.2017
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Pardo, Gabriel
- Beteiligte Personen und Organisationen
-
Jones, David E.
SpringerLink (Online service)
- DOI
-
10.1007/s00415-017-8594-9
- URN
-
urn:nbn:de:1111-201801167082
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pardo, Gabriel
- Jones, David E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers